Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 11/20 | 0.35 |
| ▸ | KRAS | P01116 | 2/20 | 0.32 |
| ▸ | JAK3 | P52333 | 3/20 | 0.32 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.32 |
| ▸ | CDK14 | O94921 | 3/20 | 0.31 |
| ▸ | CCNY | Q8ND76 | 3/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16385269 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL21879983 | 0.85 | KRAS (0.35) | TEAD1KRASJAK3 | |
| Trifluoromethanesulfonic Acid SCHEMBL21879947 | 0.83 | TEAD1 (0.34) | TEAD1KRASJAK3 | |
| Trifluoroacetic Acid SCHEMBL31257416 | 0.78 | TEAD1 (0.38) | TEAD1KRASJAK3CDK14CCNY | |
| Trifluoroacetic Acid SCHEMBL21879929 | 0.78 | BTK (0.30) | — | |
| Trifluoroacetic Acid SCHEMBL23234980 | 0.76 | CHRNB2 (0.39) | TEAD1CDK14CCNY | |
| SCHEMBL17833394 | 0.72 | JAK3 (0.40) | TEAD1JAK3 | |
| SCHEMBL17833391 | 0.72 | JAK3 (0.40) | TEAD1JAK3 | |
| SCHEMBL17833396 | 0.72 | JAK3 (0.40) | TEAD1JAK3 | |
| Trifluoroacetic Acid SCHEMBL28639089 | 0.71 | PKM (0.43) | TEAD1JAK3TEAD3CDK14CCNY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053226-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200165231-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053226-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | TEAD1 2412/4885KRAS 1/4885JAK3 3209/4885 |
| US-20200165231-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | TEAD1 2412/4885KRAS 1/4885JAK3 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.